Industry Satellite Sessions


Wednesday, May 3, 2017

14.30-15.00

N. Skalkotas Hall

Industry Satellite Lecture 1: The ALCANZA trial – A new dawn in the treatment of  relapsed/refractory CTCL
14:30-14:35
Welcome and introduction
Rudolf Stadler (Minden, Germany)
 14:35-14:50 The ALCANZA trial – Treatment of relapsed/refractory ctcl with brentuximab vedotin
Rudolf Stadler (Minden, Germany)
 14:50-14:59 Interrogating the alcanza data – What does it mean for patients and the CTCL treatment paradigm?
Rudolf Stadler (Minden, Germany)
 14:59-15:00 Closing remarks
Rudolf Stadler (Minden, Germany)
Supported by


Wednesday, May 3, 2017

14.30-15.30

MC2 Hall

Industry Satellite Symposium 1: Understanding the melanoma microenvironment
Chair: Alexander Eggermont (Paris, France)
14:30-14:35
Welcome and introductions
Alexander Eggermont (Paris, France)
14:35-14:55 Treatment combinations in melanoma: Where are we now and where are we going?
Axel Hauschild (Kiel, Germany)
14:55-15:15 The tumor microenvironment: Beyond the T cell
Michele Maio (Siena, Italy)
15:15-15:30 Panel discussion, Q&A, Closing remarks
Supported by

Wednesday, May 3, 2017

17.30-18.00

Banquet Hall

Industry Satellite Lecture 2: What do oncolytic immunotherapies mean for patients with early metastatic melanoma?
Chair: Axel Hauschild (Kiel, Germany)
Speaker: Ralf Gutzmer (Hannover, Germany)
Supported by
 

Wednesday, May 3, 2017

17.30-18.00

N. Skalkotas Hall

Industry Satellite Lecture 3: Individualized treatment strategy in melanoma
Chair: Helen Gogas (Athens, Greece)
Speaker: Ioannis Boukovinas (Thessaloniki, Greece)
Supported by


Thursday, May 4, 2017

12.45-13.45

Banquet Hall

Industry Satellite Lunch Symposium 2: Melanoma 2017: Update in Immuno-Oncology
Chair: Dimitris Bafaloukos (Athens, Greece)
12:45-12:50 Welcome and introduction
Dimitris Bafaloukos (Athens, Greece)
12:50-13:05 Adjuvant Therapy: Where are we today?
Helen Gogas (Athens, Greece)
  13:05-13:30 Considerations in clinical practice in metastatic melanoma
Michael Postow (New York, USA)
13:30-13:45 Hot topic debate
Faculty panel
13:45 Summary and close
Dimitris Bafaloukos (Athens, Greece)
Supported by


Thursday, May 4, 2017

15.30-16.30

Banquet Hall

Industry Satellite Symposium 3: The evolution of melanoma management: Where to from here?
Chair: Alexander J. Stratigos (Athens, Greece)
15:30-15:40 Welcome and Introduction
Alexander J. Stratigos (Athens, Greece)
15:40-16:00 Evolution of the science and the melanoma treatment landscape
Reinhard Dummer (Zurich, Switzerland)
16:00-16:20 Optimising treatment selection: When, with what, and in whom?
Helen J. Gogas (Athens, Greece)
16:20-16:30   Discussion and Q & A
Supported by


Thursday, May 4, 2017

18.30-19.30

N. Skalkotas Hall

Industry Satellite Symposium 4: Immuno-intervention in patients with Merkel Cell Carcinoma
Chair: Dirk Schadendorf (Essen, Germany)
18:30-18:40 Welcome and introduction
Dirk Schadendorf (Essen, Germany)
18:40-18:55 Rationale for immuno-intervention in Merkel cell carcinoma
Paul Nghiem (Seattle, USA)
18:55-19:20 Treatment approaches for Merkel cell carcinoma
Caroline Robert (Paris, France)
19:20-19:30 Q & A and close
Dirk Schadendorf (Essen, Germany)
Supported by


Friday, May 5, 2017

12.45-13.45

Banquet Hall

Industry Satellite Lunch Symposium 5: Shaping the future together: Treatment of metastatic melanoma
Chair: Georgina V. Long (Sydney, Australia)
12:45-12:55 
What does the future look like for patients with metastatic melanoma?
Georgina V. Long (Sydney, Australia)
12:55-13:05 Combining targeted therapy with immunotherapy: A rational approach
Peter Mohr (Buxtehude, Germany)
13:05-13:15 Targeted therapy and immunotherapy, a potential combination for the future: The early clinical evedence
Paolo Ascierto (Naples, Italy)
13:15-13:45 Achieving the best outcomes in metastatic melanoma today: The experts’ experience
Helen Gogas (Athens, Greece), Peter Mohr (Buxtehude, Germany), Paolo A. Ascierto (Naples, Italy)
  Facilitated by Georgina V. Long (Sydney, Australia)
Supported by


Friday, May 5, 2017

15.30-16.30

MC2 Hall

Industry Satellite Symposium 6: Optimising actinic keratosis diagnosis and management: The scale of the problem
Chairpersons: Eggert Stockfleth (Bochum, Germany) - John Lear (Manchester United Kingdom)
Speakers: Eggert Stockfleth (Bochum, Germany) - John Lear (Manchester, United Kingdom)
Supported by